×
Arcellx Net Current Debt 2021-2025 | ACLX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Arcellx net current debt from 2021 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
Arcellx Net Current Debt 2021-2025 | ACLX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Arcellx net current debt from 2021 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$228.5B
Amgen (AMGN)
$165.9B
Gilead Sciences (GILD)
$140.8B
Vertex Pharmaceuticals (VRTX)
$121.3B
Bristol Myers Squibb (BMY)
$99.6B
CSL (CSLLY)
$86.2B
GSK (GSK)
$78.3B
Regeneron Pharmaceuticals (REGN)
$61B
Alnylam Pharmaceuticals (ALNY)
$42.8B
Argenex SE (ARGX)
$36.2B
BioNTech SE (BNTX)
$27.5B
Royalty Pharma (RPRX)
$20.6B
Insmed (INSM)
$19.6B
Biogen (BIIB)
$19.4B
Illumina (ILMN)
$17B
Genmab (GMAB)
$15.2B
Genmab (GNMSF)
$14.9B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.2B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.5B
QIAGEN (QGEN)
$11.4B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.3B
Exact Sciences (EXAS)
$9.2B
Bio-Techne Corp (TECH)
$9.2B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.3B
Legend Biotech (LEGN)
$8.1B
Roivant Sciences (ROIV)
$7.7B